What are the key analytical challenges in detecting and quantifying polysorbate degradation and its byproducts, particularly at low levels?
Atanas: Polysorbates (PS) are complex, heterogeneous mixtures, making it difficult to detect low-level degradation products and distinguish between oxidative and hydrolytic pathways. Sensitive, stability-indicating methods are required, but different assays show varying selectivity toward different mechanisms of degradation. Thus, developing fit-for-purpose stability-indicating analytical methods for quantifying PS degradation requires a high degree of experience and technical depth. Understanding the mechanism(s) of degradation that are active is critical to be able to address the cause(s) of degradation.
From a formulation standpoint, what are the most critical factors that influence polysorbate stability in biologic drug products?
Satish: Polysorbate stability is influenced by factors such as raw material quality (e.g., peroxide content), presence of lipases (in the drug substance), oxygen/light exposure, as well as formulation composition. High concentrations of protein can exacerbate lipase-related degradation due to the concurrent enhancement of the concentration of lipases. Careful evaluation of these variables early on benefits from experience across multiple (drug substance) production and formulation platforms.
How are advanced analytical tools—such as high-resolution mass spectrometry or multi-dimensional chromatography—improving our understanding of degradation mechanisms?
Atanas: Advanced tools such as enzyme activity assays, LC-MS, multidimensional chromatography, and proteomics enable detailed profiling of polysorbate species and identification of host-cell lipases. These approaches improve mechanistic understanding by linking degradation products (e.g., free fatty acids (FFAs)) to specific pathways. In practice, extracting meaningful insight from such datasets requires not only access to these tools but also deep expertise in interpreting complex analytical outputs.
How can early-stage development decisions—such as excipient selection and formulation design—help mitigate long-term degradation risks?
Satish: Early selection of high-quality excipients, appropriate surfactant type/level, and robust formulation design can reduce susceptibility to oxidation. Equally important is careful downstream process development to minimise co-purification of lipases. Identifying degradation risks early avoids expensive (in time, money and resources) late-stage changes. This underscores the importance of leveraging prior knowledge and expertise across both formulation and process development during early stages.
In your view, how can mechanistic insights into lipase activity and degradation pathways inform better control strategies?
Atanas: Understanding whether degradation is oxidative or enzymatic hydrolysis is critical, as each requires distinct mitigation strategies (e.g., raw material control vs. enzyme removal). Mechanistic insight can thus directly guide formulation and process optimisation, as well as analytical monitoring strategy. However, translating these insights into actionable control strategies always depends on experience across both analytical, formulation, and process development domains, as well as a strong regulatory background.
What role do process development and manufacturing play in either accelerating or controlling polysorbate degradation?
Satish: Manufacturing plays a critical role, particularly in removing host-cell lipases through downstream processing (DSP). Optimisation of purification steps, not just for yield and quality attributes but also for lipase content, can significantly reduce risk for enzymatic degradation over the product shelf-life. Enzyme activity assays are an invaluable tool to guide such efforts. Achieving this balance often requires detailed analytical feedback and process understanding, and close cooperation between organisational functions doing this work
What role can predictive analytics or data-driven modeling play in anticipating and mitigating polysorbate degradation risks?
Atanas: Data-driven modeling can integrate analytical, process, and stability data to predict degradation risks and identify critical variables early. This enables proactive control strategies rather than reactive troubleshooting. However, building reliable predictive frameworks requires well-curated datasets and domain expertise to ensure the models reflect real-world product behavior.
How do you balance the functional benefits of polysorbates with their known stability challenges when designing robust drug products?
Satish: While polysorbates are essential for preventing protein aggregation and surface adsorption, their instability must be managed through formulation design, process development and well-designed control strategies. The balance lies in maintaining functionality while minimising degradation pathways. Critically, potential challenges should be identified and addressed as early as possible in development, as mitigation becomes significantly more difficult at later stages. This typically requires a nuanced, experience-driven approach to formulation development.
5. Can you share examples of innovative analytical approaches or case-based learnings that have significantly improved polysorbate stability assessment?
Atanas: Case studies show that combining orthogonal tools (e.g., PS profiling, lipase activity assays, and FFA quantification) can successfully identify degradation mechanisms and guide mitigation. Particle characterisation (e.g., FTIR/Raman) has also clarified whether particles are composed purely of FFAs or of FFA–protein mixtures, which is important as these cases often require different mitigation approaches. Importantly, distinguishing between oxidative and hydrolytic (lipase-driven) pathways is critical, as each requires fundamentally different mitigation strategies. In practice, we have seen numerous cases across both mechanisms where applying an integrated analytical approach has helped clarify root cause and support effective risk mitigation, highlighting the value of a comprehensive and well-coordinated analytical toolbox.
Looking ahead, what best practices should organisations adopt to ensure scalable, stable, and regulatory-compliant formulations involving polysorbates?
Satish: Organisations should adopt comprehensive control strategies combining analytical tools, raw material control, and process optimisation. Robust, stability-indicating methods and orthogonal testing are essential for scalable and compliant products. At the same time, efficient workflows are critical, as the breadth of available analytical tools can quickly make assessments complex without a structured approach. Establishing such frameworks effectively often depends on having access to highly specialised know-how.
Do you see any emerging challenges related to surfactant selection in biologic formulations?
Atanas: One emerging trend is the increasing use of alternatives such as Poloxamer 188 to mitigate known stability issues associated with polysorbates. While this approach can reduce risks related to oxidative or enzymatic degradation, it introduces new challenges, as Poloxamer 188 is generally less effective at protecting proteins against interfacial stress. As a result, a number of programs that have transitioned away from polysorbates are now encountering increased levels of proteinaceous particle formation. This highlights that surfactant selection remains a complex, product-specific decision, where mitigating one risk can inadvertently introduce another and requires careful, experience-driven evaluation.
Common questions for both the speakers:
Polysorbate degradation has emerged as a major challenge in biologics. What key scientific or industry shifts have elevated its importance in recent years?
Satish: Increased use of high-concentration biologics and improved analytical capabilities have revealed PS degradation as a major quality risk. Industry focus has shifted due to the impact of this degradation on stability, safety, and regulatory compliance. In parallel, the criticality of particles in biologic therapeutics and their potential impact on product quality and patient safety have received heightened attention from health authorities over the past 1–2 decades. Addressing these challenges requires a deeper level of analytical and mechanistic understanding than in the past.
Lipase-mediated degradation is often highlighted as a primary mechanism—how does this pathway impact different biologic modalities, and where do you see the greatest vulnerabilities?
Atanas: Lipase-driven hydrolysis is especially critical in monoclonal antibodies and other high-concentration biologic formulations, where host-cell proteins are more impactful. High concentration formulations are particularly vulnerable due to higher relative enzyme levels from co-purification. Accurately assessing this risk depends on sensitive detection methods and informed interpretation.
How does polysorbate degradation translate into downstream risks such as particle formation, stability loss, and potential immunogenicity?
Satish: Hydrolytic (lipase-catalysed) degradation leads to the liberation of free fatty acids, which can precipitate as particles and reduce available surfactant protection, resulting in aggregation and interfacial instability. These effects can compromise product quality and potentially increase immunogenicity risks.
To what extent should companies adopt an integrated control strategy across raw materials, formulation, process, and analytics, rather than addressing degradation at isolated stages?
Atanas: An integrated approach across raw material control, formulation, process, and analytics is essential because degradation mechanisms are multifactorial and efficient mitigation requires a multi-pronged control strategy. Isolated controls are insufficient to manage risks effectively across the product lifecycle. Implementing such holistic strategies benefits from cross-functional experience and coordinated analytical capabilities.
How are regulatory expectations evolving around excipient stability, and what should developers prioritise to stay ahead of compliance requirements?
Satish: Surfactants in a product are looked upon as critical excipients. Regulators, therefore, increasingly expect a thorough understanding, monitoring, and control of their stability, including degradation pathways and risks. Developers should prioritise robust analytical methods, process controls, and comprehensive characterisation to stay compliant. Meeting these expectations consistently requires both technical rigor and significant practical experience.
